Allergies News and Research

Latest Allergies News and Research

New breakthrough: Seaweed for treatment of swine flu

In a groundbreaking new discovery a Tasmanian company has used seaweed as treatment for swine flu. The lab trials have been going on for the past nine months using the undaria seaweed (better know as wakame seaweed) harvested from waters at Triabunna, of Tasmania's East Coast.

5 May 2010

Meda AB's net sales for first-quarter 2010 decrease 14% to SEK 2,943M

After a strong Q4 in 2009, net sales decreased 14% in Q1 to SEK 2,943 million (3,437). Mainly currency effects but also increased competition for Astelin and Optivar reduced sales by more than SEK 400 million, compared with the same period last year.

5 May 2010

Health IT Roundup: Many obstacles, much promise

The Boston Globe: There is a lingering "professional resistance to electronic records systems that computerization advocates say threatens the goals of the new health care overhaul law. These advocates argue that using computers to track what care patients receive, for instance, is vital to deciding what medications and treatments work best."

5 May 2010

New findings show seaweed extract inhibits H1N1 virus

In a breakthrough that offers new hope for the containment of influenza outbreaks, an Australian biotechnology company has isolated a natural extract from seaweed which has been shown to inhibit the H1N1 virus.

5 May 2010

Idera Pharmaceuticals reports net loss of $1.9M for first-quarter 2010

Idera Pharmaceuticals, Inc., a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors, today reported financial results for the first quarter ended March 31, 2010.

5 May 2010

Merck reports non-GAAP EPS of $0.83 for first-quarter 2010

Merck & Co., Inc. today announced financial results for the first quarter of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the first quarter of $0.83, which excludes purchase accounting adjustments, merger-related expenses and restructuring costs, as well as a tax charge related to the recently enacted health care reform legislation. First-quarter GAAP EPS was $0.09.

4 May 2010

AIDS 2010 to explore latest developments in HIV science

Organizers of the XVIII International AIDS Conference announced today that President Bill Clinton, founder of the William J. Clinton Foundation and 42nd President of the United States, and South African Health Minister Aaron Motsoaledi will be among 19 high-level speakers who will address an estimated 25,000 conference attendees in Vienna this summer.

4 May 2010

Novel combined immunotherapy promising for treatment of malignant brain tumors

A new Phase I clinical trial conducted at Cedars-Sinai Medical Center's Maxine Dunitz Neurosurgical Institute in Los Angeles shows that two innovative treatment approaches may safely be combined to treat patients with highly aggressive, malignant brain tumors called gliomas. The results suggest that combining the two therapies might boost their effectiveness and supports the pursuit of additional studies on this approach to treating these tumors.

4 May 2010

Updated list of emergency medications and equipment for dental providers

Best practices for managing medical emergencies in dental clinics have evolved over the past decade to account for advances in knowledge and the development of new medications and medical equipment. Morton Rosenberg, DMD, of Tufts University School of Dental Medicine and an expert on dental anesthesiology, integrated existing guidelines with new information to create an updated list of emergency medications and equipment for dental providers, including an emergency preparedness checklist.

4 May 2010

ACAAI, AGA Institute announce innovative initiative to raise awareness of HAE

The American College of Allergy, Asthma and Immunology and the American Gastroenterological Association Institute today announced an innovative initiative called "HAE: Learn About It, Talk About It," at Digestive Disease Week® 2010.

4 May 2010

NIAID researchers initiate trial of DAS181 in patients with asthma, bronchiectasis

NexBio, Inc. announced today the initiation of a trial of DAS181 (Fludase®) in patients with the respiratory conditions asthma and bronchiectasis, being conducted by researchers with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). This trial will examine the effects of DAS181 in subjects with well-controlled or stable pulmonary disease.

3 May 2010

Researchers develop asthma medical home to care children with asthma

A comprehensive, patient-centered approach to asthma care that includes education, referrals to specialists and home visits not only improves patients' health but also has tremendous potential to decrease health care costs, according to research to be presented Saturday, May 1 at the Pediatric Academic Societies annual meeting in Vancouver, British Columbia, Canada.

3 May 2010

ISTA Pharmaceuticals first-quarter net revenues up 39%

ISTA Pharmaceuticals, Inc., today reported financial results for the quarter ended March 31, 2010. First quarter 2010 net revenues were $28.3 million, an increase of 39% from the first quarter of 2009. Net income for the first quarter ended March 31, 2010, was $0.5 million, or $0.01 per share, compared to a net loss of $19.6 million, or $0.59 per share, for the first quarter ended March 31, 2009.

30 Apr 2010

REGN reports net loss of $30.5M for first-quarter 2010

Regeneron Pharmaceuticals, Inc. announced financial and operating results for the first quarter of 2010. The Company reported a net loss of $30.5 million, or $0.38 per share (basic and diluted), for the first quarter of 2010 compared with a net loss of $15.4 million, or $0.19 per share (basic and diluted), for the first quarter of 2009.

30 Apr 2010

Mylan first-quarter total revenues increase 7% to $1.29 billion

Mylan Inc. today announced its financial results for the three months ended March 31, 2010.

30 Apr 2010

$EnzymeRx reports positive results from first clinical trial of pegsitacase for refractory gout$

EnzymeRx reports positive results from first clinical trial of pegsitacase for refractory gout

EnzymeRx, LLC, a clinical-stage biotechnology company, announced top line results from its first clinical trial of pegsitacase (formerly called Uricase‑PEG 20). Pegsitacase is a pegylated uricase being developed by EnzymeRx for the treatment of refractory gout and for the management of hyperuricemia associated with tumor lysis syndrome.

30 Apr 2010

Genetic test to predict newborns requiring hospital readmission shortly after birth

The results of two separate research studies taking place at Children's Mercy Hospitals and Clinics will help physicians use genetic testing to prevent complications, and ease the worry of new parents by predicting in advance which newborns may require readmission to the hospital shortly after birth. The studies also will help physicians identify which of their young patients are likely to respond well - or not - to steroid therapy for asthma.

29 Apr 2010

Most parents restrict playtime activities for asthmatic children

New data released today find that 82 percent of parents of children ages 4-12 with asthma report having restricted playtime activities to help avoid triggers and prevent asthma attacks in their children, with 47% of them keeping children with asthma inside when allergy season is in full swing. Working parents, who more often report experiencing stress related to raising a child with asthma than non-working parents (44% vs. 38%), take more precautions, such as more often swapping carpeting for wood flooring (30% vs. 17%).

29 Apr 2010

Great American Asthma Challenge movement to change asthma care in the U.S.

Every day 10 people die from asthma. Most healthcare providers agree that these deaths are preventable. Patient education, access to care and a healthy lifestyle are proven methods that lead to less severe asthma symptoms, fewer hospitalizations and emergency department visits, fewer missed days of school and work - and fewer deaths.

29 Apr 2010

Medication-free home ventilation system designed to remove allergens

According to a recent report by USA Today, due to 2010's unusually cold winter temperatures, allergy sufferers are now poised to experience the worst pollen season in years, with pollen counts skyrocketing and sufferers hiding indoors to avoid exposure. Yet as allergens creep indoors, sufferers continue to cough, sneeze and seek relief. With the introduction of EZ Breathe, a new innovative home ventilation system designed to remove allergens and reduce indoor concentrations of pollen, allergy sufferers now have a medication-free solution.

27 Apr 2010